Andrew Allan Price, MD - Lenox Hill Hospital-Department of Medicine

100 E 77th St
New York, NY 10075

Andrew Allan Price, MD, operates within Lenox Hill Hospital's Department of Medicine in New York, NY. This esteemed facility offers a range of medical services, from primary care to cutting-edge surgical interventions, ensuring comprehensive care for all patients seeking treatment. The dedicated professionals at Lenox Hill Hospital are actively involved in medical research, education, and community health programs, striving to enhance healthcare outcomes and foster a healthier community.

Located in the bustling city of New York, Lenox Hill Hospital-Department of Medicine, under the guidance of Andrew Allan Price, MD, is at the forefront of healthcare innovation. With a commitment to excellence, the hospital remains dedicated to advancing medical technologies, participating in clinical trials, and forming strategic partnerships to better serve its patients and the surrounding communities. Patients can trust in the expertise and compassionate care provided by the skilled team at Lenox Hill Hospital, ensuring their health and well-being are the top priorities at all times.

Generated using this brand's available information

Own this business?
See a problem?

You might also like

Psychiatrists and psychoanalysts, Internal medicine practitioners

Frank J Schwab, MD - Northwell Health

Professionally, I am highly motivated and dedicated to making significant contributions to advancing Neuroradiology research and practice. Specifically, I have developed a special focus on neurological molecular imaging, with an emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease. I was awarded the Foundation of the ASNR 2021 Boerger Research Fund for Alzheimer s Disease and Neurocognitive Disorders for the project [18F] PI-2620 in Primary Progressive Aphasia (Franceschi AM, PI), with the goal of characterizing biodistribution of abnormal tau accumulation in PPA subtypes using the novel second generation tracer PI-2620 and correlating these findings with clinical disease severity and neurodegeneration. I am also PI for the project Utility of [18F] PI-2620 as Universal Biomarker for the A/T/N Classification of Dementia and Neurodegenerative Disease , which aims to establish the efficacy of PI-2620 as a single, universal biomarker for the A/T/N classification scheme of dementia, with the eventual goal of its use in descriptive classification, patient selection and target engagement assessment in disease-modifying clinical treatment trials. I contribute as a co-Investigator on the study A Life Course Approach to Integrating Trauma and Cognitive Aging: A Cohort of 9/11 Responders, which is part of the World Trade Center (WTC) responders aging program (NIH R01 AG049953; Clouston, PI). This research focuses on PTSD and WTC exposures as risk factors for cognitive dysfunction and decline in a prospective cohort of responders, alongside changes in -amyloid, tau deposition, and neurodegeneration. These varied experiences have allowed me to understand the characterization of non-Alzheimer s tauopathies, and have improved my analytical expertise to apply this knowledge to studying Alzheimer s disease and related neurocognitive disorders. In addition to multiple scientific publications on these topics, I am lead editor of the textbook Hybrid PET/MR Neuroimaging: A Comprehensive Approach (Springer Nature, 2022).
United StatesNew YorkNew YorkAndrew Allan Price, MD - Lenox Hill Hospital-Department of Medicine

Partial Data by Infogroup (c) 2025. All rights reserved.